The treatment window that makes early assessment matter

Mytocel MSK has a defined, evidence-supported population: people with knee osteoarthritis at Kellgren-Lawrence (KL) grades I–III, where at least part of the articular cartilage is still present. That cartilage residue is central to the procedure's biological rationale. The AMT® micrograft suspension delivers autologous biological components that stimulate the tissue's own repair mechanisms; when bone-on-bone wear has removed that substrate entirely, the biological basis for an orthobiologic intervention of this kind no longer holds in the same way.

The Bioengineering 2023 pilot study (Tsoukas et al.) built this principle directly into its eligibility criteria, including 10 patients aged 37–84 with early-stage knee osteoarthritis and making grade 4 an explicit exclusion. The manufacturer FAQs confirm the same threshold, noting that for late grade III and grade IV there is insufficient clinical evidence to establish Mytocel MSK as a standard indication.

The practical consequence is straightforward: OA grade does not remain fixed. Cartilage wear advances, and the grades I–III window is time-limited for any individual. Clinician assessment is the structural step that establishes — through radiographic grading, imaging, and clinical examination — whether a patient is still within that window and whether Mytocel MSK represents an appropriate, well-evidenced course of action. Identifying that opportunity while the joint can still support the procedure's biology is precisely what makes timely assessment valuable.

What the Kellgren-Lawrence scale tells the clinician

The Kellgren-Lawrence scale runs from grade 0 (no radiographic changes) to grade IV (complete joint-space loss, bone on bone). In practical terms: grade I shows minor osteophyte formation with no measurable space narrowing; grade II adds definite osteophytes and possible narrowing; grade III brings moderate narrowing with multiple osteophytes; grade IV indicates severe loss with subchondral sclerosis. Grades I–III are the joints that still carry some articular cartilage — the biological substrate the AMT® micrograft suspension is designed to work alongside.

Pain intensity alone cannot reliably place a patient within that window. Structural grade and symptom burden correlate poorly in mild-to-moderate OA: some people with grade III changes report manageable discomfort, while others with grade I findings present in significant pain. Relying on symptom impression risks both over-treating joints already past the evidence-supported range and — more commonly — delaying referral until the window has closed.

Imaging helps establish the structural picture alongside symptoms and clinical examination. X-ray provides the Kellgren–Lawrence grade, while MRI may add detail about cartilage and other joint structures when clinically indicated. The clinical data template provides fields for both KL and Outerbridge scores, but imaging choices should follow the applicable protocol and clinician judgement.

Together, KL grade and Outerbridge score give the clinician a precise, reproducible account of where the joint stands — and whether it remains within the evidence-supported indication for Mytocel MSK.

What a full pre-procedure assessment covers

Alongside the imaging results the workup has already gathered, the full pre-procedure protocol draws on symptom history, functional status, and a metabolic panel — HbA1c, ESR, Vitamin D3, B12, and lipid profile. Each element serves a specific purpose. Metabolic factors such as uncontrolled blood glucose or vitamin deficiency can affect the biological environment the micrografts enter; identifying and addressing them before treatment is part of optimising the conditions in which the AMT® suspension is asked to work.

At the same appointment, the clinician administers the KOOS questionnaire — a validated, patient-reported instrument covering pain, symptoms, daily function, sport and recreation, and quality of life. Its value extends well beyond the consultation room: because KOOS is re-administered at every scheduled follow-up, that first completion becomes the reference point against which all post-treatment change is measured. The assessment is, in that sense, the opening moment of a continuous, structured outcome-tracking programme.

Contraindication screening completes the workup and functions as a patient safeguard. Active infection in or near the target joint, active autoimmune disease requiring immunosuppression, current corticosteroid use, and hyaluronic acid injection within the previous six months each preclude the procedure — not as administrative barriers, but because they affect either the safety of an intra-articular intervention or the biological conditions the AMT® solution depends upon. Confirming their absence ensures that Mytocel MSK proceeds only where its clinical and biological basis is intact.

How assessment routes the right patient to the right intervention

The findings that the assessment assembles — KL grade, Outerbridge cartilage depth, symptom trajectory — do not simply confirm eligibility; they actively select the appropriate intervention.

For a grade I–III knee with preserved articular cartilage, the biological rationale for Mytocel MSK is at its strongest. The AMT® micrograft suspension delivers autologous biological components to a joint that still has tissue capable of responding to them. Hyaluronic acid serves a different purpose: short-term lubrication and symptom relief, without acting on the underlying tissue biology. At the London Cartilage Clinic this distinction is made explicit — "which treatment is appropriate is settled on examination and imaging," not by a default pathway applied before the patient is seen.

Where imaging reveals more advanced cartilage loss or findings outside the evidence-supported Mytocel MSK population, assessment helps the clinician direct the patient to an appropriate alternative pathway rather than overextending this procedure.

That structured, grade-matched routing is precisely what makes clinician assessment the genuine gateway to care. Mytocel MSK's place as the recommended biological option for confirmed grade I–III patients is a clinical precision, not a restriction — it reflects the evidence base accurately and ensures the procedure is applied where its biological rationale is soundest.

The Mytocel MSK procedure the confirmed patient receives

Once assessment confirms grade I–III suitability, the Mytocel MSK procedure takes place entirely in an ambulatory setting — an outpatient clinical setting under sterile conditions, without general anaesthesia, and no manufactured cell product.

Three 2.5 mm cartilage punches are taken from the posterior auricular concha under local anaesthetic. The samples are placed in the Rigeneracons® RS disposable device with saline and mechanically disaggregated for approximately six minutes using the N4SA 2.0 motorised unit. The result is an autologous, tissue-specific micrograft suspension — derived entirely from the patient's own cartilage and prepared at the point of care.

That tissue-specific origin is central to the biological rationale. Pre-clinical and clinical studies have demonstrated that AMT® autologous micrograft solutions contain mesenchymal stem cells capable of modulating innate and adaptive immune responses through growth factors, exosomes, chemokines and immunosuppressive molecules (Shi et al., 2018). The suspension is then administered directly into the affected knee joint. The auricular donor site requires no sutures and heals completely within one to two weeks, typically without visible scarring.

The clinical evidence for this population rests on the Tsoukas et al. pilot study (Bioengineering, 2023), which concluded that the AMT® protocol is effective and safe for early-stage knee osteoarthritis in its study population. The authors noted that a larger randomised controlled trial is needed to validate the findings at scale — the natural next step for an emerging orthobiologic approach with a defined, evidence-supported indication.

KOOS outcomes: from baseline assessment to post-treatment progress

In the Tsoukas et al. pilot study (Bioengineering, 2023), KOOS served as the primary outcome instrument in its early-stage knee osteoarthritis cohort — and the study concluded that the AMT® protocol is effective and safe for early-stage knee osteoarthritis. That conclusion was reached by tracking KOOS scores from the T0 baseline through each successive follow-up point, converting the reference score recorded at assessment into a reproducible measure of individual change rather than a one-time snapshot.

The structural consequence of that design matters. The same assessment infrastructure that gates entry to the Mytocel MSK pathway — KL grade, Outerbridge score, clinical history, and the initial KOOS — continues as the monitoring framework after treatment. Each follow-up score is compared against a clinician-verified individual baseline, not a population average, making functional progress tangible and documented rather than impressionistic.

In the Tsoukas study, KOOS provided a consistent way to compare each patient's baseline with one- and six-month follow-up. Those encouraging results support further evaluation of Mytocel MSK while remaining distinct from evidence for other cell-based or injectable procedures.